🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

127 results for “Jin” Clear

  1. AVP-786 matching Placebo, AVP-786, AVP-786

    Otsuka Beijing Research Institute

    Agitation in Patients With Dementia of the Alzheimer's Type

    phase 3 small molecule active

    1 trial

  2. AVP-786 matching placebo, AVP-786

    Otsuka Beijing Research Institute

    Agitation in Patients With Dementia of the Alzheimer's Type

    phase 3 small molecule active

    1 trial

  3. Aripiprazole

    Otsuka Beijing Research Institute

    Bipolar I

    phase 3 small molecule completed

    1 trial

  4. Aripiprazole IM Depot

    Otsuka Beijing Research Institute

    Schizophrenia

    phase 3 small molecule completed

    1 trial

  5. Delamanid + OBR

    Otsuka Beijing Research Institute

    Multidrug-resistant Tuberculosis

    phase 3 small molecule completed

    1 trial

  6. Escitalopram

    Otsuka Beijing Research Institute

    Major Depressive Disorder (MDD)

    phase 3 small molecule terminated

    1 trial

  7. Fenofibrate

    Xijing Hospital of Digestive Diseases

    Primary Biliary Cirrhosis

    phase 3 small molecule active

    1 trial

  8. Gum chewing

    Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co.,

    Recovery of Bowel Function, Due to Gum Chewing

    phase 3 other active

    1 trial

  9. JNT-517 Placebo, JNT-517, JNT-517

    Otsuka Beijing Research Institute

    Phenylketonuria

    phase 3 small molecule active

    1 trial

  10. Jinarc 30 mg tablets, Tolvaptan, Jinarc 15 mg tablets, Samsca 7.5 mg tablets

    Otsuka Beijing Research Institute

    Autosomal Recessive Polycystic Kidney Disease

    phase 3 small molecule active

    1 trial

  11. Lidocaine spray

    Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co.,

    Uterine Bleeding

    phase 3 small molecule completed

    1 trial

  12. Lidocaine spray

    Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co.,

    Uterine Cervical Dysplasia

    phase 3 other completed

    1 trial

  13. MCV-ACYW135 Vaccine Group

    Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

    Meningitis

    phase 3 mab completed

    1 trial

  14. Mevac-A vaccine

    Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co.,

    HAV

    phase 3 mab completed

    1 trial

  15. Mimetic granules of Yiqi-Wenjing prescriptions

    The First People's Hospital of Lianyungang

    Chemotherapy-induced Peripheral Neuropathy

    phase 3 small molecule active

    1 trial

  16. Sibeprenlimab 400 mg

    Otsuka Beijing Research Institute

    Immunoglobulin A Nephropathy

    phase 3 small molecule active

    1 trial

  17. Sibeprenlimab 400 mg s.c. Q4weeks

    Otsuka Beijing Research Institute

    Immunoglobulin A Nephropathy

    phase 3 small molecule active

    1 trial

  18. Tolvaptan

    Otsuka Beijing Research Institute

    Autosomal Recessive Polycystic Kidney Disease

    phase 3 small molecule active

    1 trial

  19. Tolvaptan

    Otsuka Beijing Research Institute

    Cardiac Edema

    phase 3 small molecule completed

    1 trial

  20. pneumococcal disease prevention

    Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

    Pneumococcal Vaccines

    phase 3 mab active

    1 trial

  21. rt-PA

    Beijing Tiantan Hospital

    Acute Ischemic Stroke

    phase 3 small molecule completed

    1 trial

  22. Bortezomib

    Jin Lu, MD

    Systemic Amyloidosis

    phase 2 small molecule active

    1 trial

  23. Camrelizumab Plus Apatinib

    Nanjing Zenshine Pharmaceuticals

    Unresectable Hepatocellular Carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  24. DIABECELL(R)

    Otsuka Beijing Research Institute

    Type 1 Diabetes

    phase 2 other completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources